A recent pooled analysis of EMPEROR-Reduced and EMPEROR-Preserved (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure with Reduced or Preserved Ejection Fraction, respectively) demonstrated that the benefit of empagliflozin on heart failure events was not influenced by KDIGO categories based on eGFR and urine albumin-to-creatinine ratio (Butler et al., 2023). Here, ALB is linked to congestive heart failure.